Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

The UK plans to test US firm Eli Lilly' s weight loss jab Mounjaro to help the burden on the national healthcare system. Over ...

DEMAND for fat jabs could overwhelm the NHS, the head of the health service has warned as Sir Keir Starmer piled hopes on using them to get obese jobseekers back to work. Amanda Pritchard, CEO of ...

Conclusion: The Karnataka High Court, upholding the ITAT’s order, reiterated that discounts on the issuance of ESOPs are allowable deductions under Section 37 (1) of the Income Tax Act, in line with ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

A study will assess changes in employment status and sick days when people take the drug. Weight loss drugs could be given to unemployed people with obesity as a way of getting them into work, British ...

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical ...

Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

Drugs like Ozempic and Wegovy may provide a surprising, life-saving benefit for the youngest patients taking these diabetes and weight loss medications.

AZN currently has a forward P/E ratio of 19.02, while NVO has a forward P/E of 39.15. We also note that AZN has a PEG ratio ...